Every Form 4 that Bioventus Inc. (BVS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BVS filings page.
Bioventus Inc. director and 10% owner John A. Bartholdson reported equity compensation and vesting-related transactions with no open-market buying or selling. He received a grant of 25,146 restricted stock units, each representing one share of Class A common stock, at no cash cost.
On a prior date, 32,282 restricted stock units vested and were exercised into 32,282 shares of Class A common stock, leaving no units remaining from that award and resulting in 111,902 directly held shares. He also reports indirect ownership of 6,939,357 shares through Juniper investment entities, over which he shares voting and dispositive power and disclaims beneficial ownership beyond his pecuniary interest. The new RSU grant will vest on the earlier of the day immediately preceding the first Annual Meeting of Stockholders after grant or the first anniversary of grant, subject to continued board service.
Bioventus director and 10% owner Martin P. Sutter reported equity compensation and related share movements. On June 3, 2026, he received a grant of 25,146 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A common stock, scheduled to vest based on future board service conditions. On June 2, 2026, 32,282 RSUs vested and were exercised, delivering the same number of Class A shares and bringing his direct Class A holdings to 117,523 shares. The filing also shows 13,021,324 Class A shares held indirectly through EW Healthcare Partners Acquisition Fund, L.P. and White Pine Medical, LLC, where Sutter is one of several managers; these managers disclaim beneficial ownership except to the extent of their pecuniary interests.
Bioventus Inc. director Susan M. Stalnecker reported equity compensation activity involving restricted stock units (RSUs) and common shares. On June 3, 2026, she received a grant of 25,146 RSUs, each representing a contingent right to one share of Class A common stock.
On June 2, 2026, 32,282 RSUs vested and were exercised into 32,282 shares of Class A common stock at no cash exercise price. Following these transactions, she holds 138,239 shares of Class A common stock directly, along with 25,146 RSUs that will vest based on future service conditions.
Bioventus Inc. director Guy P. Nohra reported equity compensation activity consisting of a new grant of restricted stock units and the vesting of a prior award. On June 3, 2026, he received 25,146 restricted stock units, each representing a contingent right to one share of Class A common stock. On June 2, 2026, 32,282 restricted stock units vested and were exercised into 32,282 shares of Class A common stock, leaving him with 148,892 shares held directly after the transactions. These filings reflect routine equity awards and vesting rather than open-market purchases or sales.
Bioventus Inc. director Guido J. Neels reported routine equity compensation activity. On June 3, 2026, he received a grant of 25,146 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A common stock, subject to future vesting conditions tied to board service. On June 2, 2026, a prior RSU award for 32,282 units vested and was exercised, converting into 32,282 shares of Class A common stock at no cash cost. Following these transactions, he directly holds 117,523 shares of Class A common stock, with the exercised RSU award fully settled.
Bioventus Inc. director Michelle McMurry-Heath reported equity compensation and a vesting event. On June 2, 2026, 32,282 restricted stock units were exercised and converted into the same number of shares of Class A common stock, leaving her with 77,279 shares held directly. Each RSU represents a contingent right to receive one share of Class A common stock, and the RSUs referenced in the footnotes vest based on service on the Board and the timing of the company’s annual stockholder meeting. On June 3, 2026, she also received a grant of 25,146 RSUs as additional equity compensation, which will vest according to the disclosed schedule.
Bioventus Inc. director Mary Kay Ladone reported equity compensation and an option-style exercise of prior awards. On June 3, 2026 she received a grant of 25,146 Restricted Stock Units (RSUs), each representing the right to receive one share of Class A common stock. On June 2, 2026, 32,282 RSUs vested and were exercised into 32,282 shares of Class A common stock, increasing her direct holdings to 111,263 shares. The newly granted RSUs will vest based on continued board service through the earlier of the company’s next Annual Meeting of Stockholders or the first anniversary of grant.
Bioventus Inc. director William A. Hawkins reported equity compensation activity involving restricted stock units (RSUs) and Class A common stock. On June 3, 2026, he received a grant of 30,994 RSUs, each representing a contingent right to receive one share of Class A common stock, with vesting tied to continued board service.
On June 2, 2026, 39,789 RSUs vested and were exercised into 39,789 shares of Class A common stock. Following these transactions, Hawkins directly owned 297,640 shares of Class A common stock and held 30,994 RSUs as a separate derivative position, reflecting routine director compensation and vesting rather than open-market trading.
Bioventus Inc. director Philip G. Cowdy reported equity compensation changes. He received a grant of 25,146 restricted stock units (RSUs), each representing one share of Class A common stock, which will vest based on continued board service. A separate RSU award for 32,282 units vested and was exercised into 32,282 shares of Class A common stock, leaving him with 43,982 common shares directly held and 25,146 RSUs outstanding. These transactions reflect compensation awards and option-like exercises rather than open-market buying or selling.
Bioventus Inc. director Pat Beyer reported equity compensation activity and an option-like vesting event. On June 3, 2026, Beyer received a grant of 25,146 restricted stock units, each representing a contingent right to one share of Class A common stock. These RSUs will vest on the earlier of the day immediately preceding the issuer's first annual meeting of stockholders following the grant date or the first anniversary of the grant, subject to continued board service.
On June 2, 2026, previously granted RSUs vested and were exercised into 32,282 shares of Class A common stock, eliminating that RSU balance. Following these transactions, Beyer holds 108,718 shares of Class A common stock directly and 25,146 RSUs that remain outstanding.
Cowdy Philip G. reported acquisition or exercise transactions in this Form 4 filing.
Bioventus Inc. filed an amended insider report for director Philip G. Cowdy to correct a previously reported grant of 2,700 Restricted Stock Units dated April 1, 2021. A footnote explains the earlier Form 4 was filed inadvertently for RSUs that were not accepted, and that as of April 1, 2021, Cowdy held no non-derivative or derivative securities of Bioventus.
Cowdy Philip G. reported acquisition or exercise transactions in this Form 4 filing.
Bioventus Inc. director Philip G. Cowdy filed an amended insider report to correct a previously reported equity grant. A prior Form 4 had shown a grant of 9,000 restricted stock units, but the footnote explains this grant was not accepted. As of February 11, 2021, he held no non-derivative or derivative securities of Bioventus.
Bioventus Inc. SVP & CFO Mark Leonard Singleton exercised 13,000 Restricted Stock Units into Class A common stock on April 10, 2026. To cover tax obligations, 5,648 shares of Class A common stock were withheld at $9.06 per share. After these transactions, he directly holds 177,333 shares of Class A common stock. Each RSU represents a contingent right to receive one share and vests in four equal installments on each of the first four anniversaries of April 10, 2023, subject to continued service.
Bioventus Inc. executive Katrina J. Church, SVP & Chief Compliance Officer, exercised restricted stock units on April 10, 2026, receiving 4,300 shares of Class A common stock at a conversion price of $0.00 per share. Of these, 1,868 shares of Class A common stock were withheld at $9.06 per share to satisfy tax obligations, a non-market tax-withholding disposition. After these transactions, she directly owned 64,164 shares of Class A common stock. The footnotes explain that each RSU represents a right to receive one share of Class A common stock and that the RSUs vest in four equal installments on each of the first four anniversaries of April 10, 2023, subject to continued service.
Bioventus Inc. SVP & General Counsel Anthony D'Adamio exercised restricted stock units into shares of Class A common stock. On April 10, 2026, he converted 9,925 RSUs into 9,925 shares of Class A common stock at a conversion price of $0.00 per share.
To cover tax obligations related to this equity compensation, 4,312 shares of Class A common stock were disposed of at $9.06 per share through a tax-withholding transaction, which is not an open-market sale. Following these transactions, he directly holds 153,655 shares of Class A common stock.
Bioventus Inc. SVP & CFO Mark Leonard Singleton reported routine equity compensation activity in the form of restricted stock units. On March 20, 2026, he exercised 18,625 RSUs, receiving the same number of shares of Class A common stock at a stated price of $0.00 per share.
To cover tax obligations related to this vesting, 8,091 shares of Class A common stock were withheld at $8.64 per share, classified as a tax-withholding disposition rather than an open-market sale. After these transactions, Singleton directly held 169,981 shares of Class A common stock.
Bioventus Inc. SVP & CFO Mark Leonard Singleton reported multiple equity compensation transactions in company stock. He received 104,000 restricted stock units and a stock option for 116,000 shares of Class A common stock at an exercise price of $8.6200 per share, both granted on March 13, 2026. He also reported earlier grants from March 14, 2025 of 54,000 RSUs and a stock option for 61,000 shares at $9.6100 per share. On the same 2026 date, he exercised 13,500 RSUs into 13,500 shares of Class A common stock, with 5,865 shares withheld to cover tax obligations. After these transactions, he directly holds 159,447 shares of Class A common stock. The RSUs and options vest in four equal annual installments starting on March 15, 2025 and March 15, 2026, subject to his continued service.
Bioventus Inc. senior vice president and chief compliance officer Katrina J. Church received new equity awards and exercised existing awards. On March 13, 2026 she was granted 24,000 restricted stock units and 27,000 stock options with an exercise price of $8.62 per share, all vesting in four annual installments starting March 15, 2026, subject to continued service.
Church also exercised a total of 6,955 restricted stock units into Class A common stock, with 3,022 shares withheld to cover tax obligations. After these transactions she directly holds 61,732 shares of Class A common stock, plus outstanding RSU and option awards disclosed in the filing.
Bioventus Inc. senior vice president and general counsel Anthony D'Adamio reported multiple equity compensation transactions in Class A common stock and related derivatives. On March 13, 2026, he received grants of 83,000 restricted stock units (RSUs) and 92,000 stock options with an exercise price of $8.62 per share, expiring on March 13, 2036. Each RSU represents a right to receive one share of Class A common stock. The RSUs and options granted in 2025 and 2026 vest in four equal annual installments beginning on March 15, 2025 and March 15, 2026, subject to his continued service. On the same 2026 date, he exercised 8,886 and 8,750 RSUs into the same number of Class A shares, and the company withheld 3,861 and 3,802 shares at a price of $8.62 per share to cover tax obligations. Following these transactions, he directly owned 148,042 shares of Bioventus Class A common stock.
Bioventus Inc. President and CEO Robert E. Claypoole reported equity compensation changes and an option-related share delivery. On March 13, 2026, he exercised 33,500 restricted stock units into 33,500 shares of Class A common stock at $0.00 per share and had 14,553 shares withheld at $8.62 per share to cover tax obligations, leaving 135,944 Class A shares held directly.
On the same date, he received grants of 278,000 restricted stock units and 309,000 stock options for Class A common stock, with the options carrying an exercise price of $8.62 and expiring on March 13, 2036. Footnotes state that the RSUs and options granted in 2025 and 2026 vest in four equal annual installments starting on the first four anniversaries of March 15, 2025 and March 15, 2026, subject to his continued service.
Bioventus Inc. director Michelle McMurry-Heath reported an open-market sale of 12,000 shares of Class A common stock. The shares were sold at a weighted average price of $8.7866, in multiple trades between $8.73 and $8.81. After the transaction, she directly holds 44,997 shares.
Bioventus Inc. SVP & CFO Mark Leonard Singleton reported RSU vesting and related share movements. On February 15, 2026, 20,153 Restricted Stock Units were converted into 20,153 shares of Class A common stock at $0.00 per share.
Each RSU represents a right to receive one share of Class A common stock. To cover tax obligations, 9,429 Class A shares were disposed of at $8.27 per share in a tax-withholding transaction. After these transactions, Singleton directly owned 151,812 shares of Class A common stock and 40,304 RSUs, subject to time-based vesting conditions tied to continued service.
Bioventus Inc. senior vice president and chief compliance officer Katrina J. Church exercised restricted stock units and received Class A common shares. On February 15, 2026, 4,375 restricted stock units were converted, resulting in 4,375 shares of Class A common stock. A separate transaction shows 2,133 Class A shares were disposed of at $8.27 per share to cover tax obligations tied to this equity award. After these transactions, she directly holds 57,799 shares of Class A common stock and 8,750 restricted stock units. Each restricted stock unit represents a contingent right to one Class A share and vests in four equal installments on each of the first four anniversaries of February 15, 2024, assuming she continues in service.
Bioventus Inc. SVP & General Counsel Anthony D'Adamio reported equity award activity involving restricted stock units and Class A common stock. On February 15, 2026, he acquired 12,980 shares of Class A common stock at $0.00 per share through the exercise or conversion of restricted stock units, increasing his direct holdings of Class A common stock to 144,396 shares.
On the same date, 6,327 shares of Class A common stock were disposed of at $8.27 per share in a tax-withholding disposition, leaving him with 138,069 directly held shares. Each restricted stock unit represents a contingent right to receive one share of Class A common stock and vests in four equal installments on each of the first four anniversaries of February 15, 2024, subject to his continued service.
Bioventus Inc. President and CEO Robert E. Claypoole reported equity award activity involving the company’s Class A common stock. On January 9, 2026, 93,750 restricted stock units were converted into 93,750 shares of Class A common stock at an exercise price of $0. On the same date, 41,717 shares of Class A common stock were withheld at a price of $8.03 per share, typically reflecting shares withheld to cover taxes, leaving Claypoole with 116,997 shares of Class A common stock held directly after these transactions. Following the conversion, he also held 187,500 restricted stock units, each representing a contingent right to receive one share of Class A common stock. These RSUs vest in four equal installments on each of the first four anniversaries of January 10, 2024, subject to his continued service.
Bioventus Inc. (BVS) reported an insider transaction on a Form 4. A director sold 17,701 shares of Class A common stock on 11/07/2025 at a weighted average price of $7.4151. The filing notes multiple trades executed between $7.36 and $7.43.
Following the sale, the reporting person beneficially owns 56,997 shares, held directly. The transaction is coded “S,” indicating an open‑market or private sale. The filing was made by one reporting person.